Mölnlycke Health Care Announces $8M USD Investment in Siren

GOTHENBURG, Sweden—Mölnlycke Health Care, a medical technology company specializing in wound care solutions, announced an $8 million (USD) investment in Siren, a health care technology company. Siren aims to help reduce the risk of diabetic foot ulcers (DFU) by early detection of potential injuries through temperature-sensing textile technology.

“Our strategic investment in Siren reflects our commitment to integrating into digital ecosystems and pioneering innovative digital solutions that revolutionize health care delivery,” said Zlatko Rihter, CEO of Mölnlycke. “Helping to prevent wounds from occurring is also in line with Mölnlycke’s wound care mission to help free patients from the burden of wounds, and our ambition to further support health care in the post-acute segment.” 

Siren has developed multiple DFU products, including “the Siren sock” and a remote patient monitoring clinical team that helps patients at risk of DFU. These systems have helped reduce the risk of ulcers by up to 68% and amputations by 83% among users. 

“We’re excited to team up with Mölnlycke to tackle diabetic foot ulcers at their earliest stages,” said Ran Ma, co-founder and CEO of Siren. “By investing in preventive technologies like ours, Mölnlycke is demonstrating real vision and leadership in helping patients avoid the debilitating consequences of diabetic foot ulcers. Their investment sends a clear message that prevention matters. By catching issues before they escalate, we can help patients stay healthy and independent, reduce unnecessary procedures and ultimately make a real difference in their lives.”

The investment aims to help fight against DFU by combining Mölnlycke’s wound care knowledge with Siren technology. Together, the companies seek to enhance patient outcomes, reduce health care costs and alleviate the burden on health care providers.